

November 14, 2022

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Christopher Edwards
Jordan Nimitz
Kevin Vaughn
Christine Wong

**Re: Bionomics Limited
Registration Statement on Form F-1
File No. 333-268314**

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "*Securities Act*"), Aegis Capital Corp. and Berenberg Capital Markets LLC hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m. Eastern Time, November 15, 2022, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.

By: AEGIS CAPITAL CORP.

By: /s/ Griffin Cassagne

Name: Griffin Cassagne

Title: Executive Vice President

By: **BERENBERG CAPITAL MARKETS LLC**

By: /s/ Zachary Brantly

Name: Zachary Brantly

Title: Head of U.S. Investment Banking

By: /s/ Matthew Rosenblatt

Name: Matthew Rosenblatt

Title: CCO & Ops Principal